The story · written by gpt-6,
Cyprus published detailed rules for licensed medical-cannabis production and pharmacy supply on 6 March 2019. They provided an initial opening for three producers, alongside prescription requirements and separate approval for patients under eighteen.
A patient exception preceded the production system
The country had already announced cannabis oil for advanced cancer in 2017. Its Health Ministry described access through individual approval, a doctor’s prescription and a designated chemist.
The 2019 changes addressed a wider chain of activity: growing plants, producing and testing medical cannabis, moving it through authorised premises and supplying pharmacies.
An amendment published earlier that month supplied additional powers over licences, imports and regulatory enforcement. The detailed medical regulations then set out how the authorised system would operate.
Three producers formed the planned opening
The rules required an invitation for expressions of interest before applications for the initial three producer licences. They also protected the initial group against additional licences for a period of up to fifteen years while the relevant licences remained valid.
Applicants had to identify their premises, responsible staff, proposed activities, security measures and record systems. Specified personnel needed clean criminal-record certificates, and premises were subject to inspection.
The regulator could import medical cannabis to meet patient needs when licensed producers could not supply enough because of production or import problems. Quality testing and controls over imports and exports formed part of the system.
Prescribing rules addressed adults and minors differently
Doctors could prescribe pharmacy-prepared cannabis medicines for adults where they considered it appropriate. For a patient under eighteen, the treating doctor had to make a scientifically justified application for approval.
Prescriptions had to specify the product, THC and CBD content, dose, method of administration and quantity. The rules limited repeat use of the prescription and required the pharmacist to obtain written patient consent concerning side effects.
Smoking was excluded as a prescribed method. The regulations also restricted medical use in workplaces, schools and specified public settings.
Imported oils supplied a later documented step
In February 2021, supplier Panaxia said the production regulations still awaited implementation when it secured a government order for imported oils. The following month it announced its first delivery to Cyprus.
The government could buy imported oils for pharmacy distribution while the domestic production framework developed. Patients seeking cannabis treatment in Cyprus depended on that authorised supply chain as well as the prescribing rules.[1][2][3][4][5]
Listed for context. No score change is recorded for Cyprus here.
References
- Cyprus Health Ministry — original medical-cannabis regulations, 6 March 2019KDP 73/2019; regulations 3–7, 17–24 and 94–95; visually checked printed pp. 378, 381, 385, 387, 389 and 414; three-producer opening, fifteen-year protection, adult prescribing and separate approval for minorsarchived
- Cyprus — original drug-law amendment, gazette 1 March 2019Law 10(I)/2019; plant/seed imports, licensing procedures, regulatory exceptions and enforcement powers; statutory basis for accompanying medical regulationsarchived
- Cyprus Health Ministry press officer Margarita Kyriakou — explanation of cannabis-oil access, 23 July 2017Signed ministry statement published in Cyprus Mail: named-patient request and medical report, ministerial exception, doctor’s prescription, Pharmaceutical Services and designated chemistarchived
- Panaxia — Cyprus government selects medical-cannabis oils, company announcement 3 February 2021Company primary statement: order/import permits, two Panaxir oil concentrations, EU-GMP manufacture; describes existing minister-approved pharmacy routearchived
- Jerusalem Post — Panaxia announces first delivery to Cyprus, 26 March 2021Reports company announcement on Thursday 25 March, following Israeli ministry/customs checks; products sold to government for pharmacy distribution; first Panaxia delivery, not first-ever cannabis importarchived
Checked. The date and the event were compared with a source that was read.